JP2006516140A - 有糸分裂キネシン阻害剤 - Google Patents

有糸分裂キネシン阻害剤 Download PDF

Info

Publication number
JP2006516140A
JP2006516140A JP2004563641A JP2004563641A JP2006516140A JP 2006516140 A JP2006516140 A JP 2006516140A JP 2004563641 A JP2004563641 A JP 2004563641A JP 2004563641 A JP2004563641 A JP 2004563641A JP 2006516140 A JP2006516140 A JP 2006516140A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
heterocyclyl
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004563641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516140A5 (enExample
Inventor
フラリー，マーク・イー
ガルバツチヨ，ロバート・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2006516140A publication Critical patent/JP2006516140A/ja
Publication of JP2006516140A5 publication Critical patent/JP2006516140A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004563641A 2002-12-20 2003-12-16 有糸分裂キネシン阻害剤 Ceased JP2006516140A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43510202P 2002-12-20 2002-12-20
PCT/US2003/040126 WO2004058148A2 (en) 2002-12-20 2003-12-16 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
JP2006516140A true JP2006516140A (ja) 2006-06-22
JP2006516140A5 JP2006516140A5 (enExample) 2010-07-15

Family

ID=32682157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563641A Ceased JP2006516140A (ja) 2002-12-20 2003-12-16 有糸分裂キネシン阻害剤

Country Status (6)

Country Link
US (1) US7622468B2 (enExample)
EP (1) EP1581497A4 (enExample)
JP (1) JP2006516140A (enExample)
AU (1) AU2003297230B2 (enExample)
CA (1) CA2509212A1 (enExample)
WO (1) WO2004058148A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058700A2 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2007515945A (ja) * 2003-05-30 2007-06-21 ロゼッタ インファーマティックス エルエルシー キネシン活性の調節因子を同定するための方法
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
WO2009052288A1 (en) 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN103804283B (zh) * 2012-11-06 2016-04-20 中国科学院大连化学物理研究所 一种制备1,2-二氢吡啶衍生物的方法
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104756984B (zh) * 2015-03-30 2016-08-17 上海应用技术学院 多取代顺式二苯乙烯类化合物作为农用杀菌剂的应用
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076459B1 (en) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6422869A (en) * 1987-06-24 1989-01-25 Lundbeck & Co As H Heterocyclic compound
JPH01203380A (ja) * 1987-12-22 1989-08-16 Merck Sharp & Dohme Ltd メチルテトラヒドロピリジルオキサジアゾール類
JPH04235985A (ja) * 1990-05-31 1992-08-25 Merck Sharp & Dohme Ltd 緑内障の治療に使用するための置換オキサジアゾール類及びチアジアゾール類及びその用途を有する新規な化合物
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
JP2005536479A (ja) * 2002-06-14 2005-12-02 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
JP2006506456A (ja) * 2002-10-18 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
WO2004058700A2 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6422869A (en) * 1987-06-24 1989-01-25 Lundbeck & Co As H Heterocyclic compound
JPH01203380A (ja) * 1987-12-22 1989-08-16 Merck Sharp & Dohme Ltd メチルテトラヒドロピリジルオキサジアゾール類
JPH04235985A (ja) * 1990-05-31 1992-08-25 Merck Sharp & Dohme Ltd 緑内障の治療に使用するための置換オキサジアゾール類及びチアジアゾール類及びその用途を有する新規な化合物
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
JP2005536479A (ja) * 2002-06-14 2005-12-02 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
JP2006506456A (ja) * 2002-10-18 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤

Also Published As

Publication number Publication date
WO2004058148A2 (en) 2004-07-15
EP1581497A2 (en) 2005-10-05
US20060058327A1 (en) 2006-03-16
WO2004058148A3 (en) 2004-09-16
US7622468B2 (en) 2009-11-24
EP1581497A4 (en) 2009-03-18
AU2003297230B2 (en) 2009-11-26
AU2003297230A1 (en) 2004-07-22
CA2509212A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
JP4590270B2 (ja) 有糸分裂キネシン阻害剤
JP4391825B2 (ja) 有糸分裂キネシン阻害剤
JP4467979B2 (ja) 有糸分裂キネシン阻害剤
JP4463679B2 (ja) 有糸分裂キネシン阻害剤
JP4597519B2 (ja) 有糸分裂キネシン阻害薬
JP4399269B2 (ja) 有糸分裂性キネシン阻害薬
JP4377323B2 (ja) 有糸分裂キネシン阻害剤
US7622468B2 (en) Mitotic kinesin inhibitors
CN100548296C (zh) 有丝分裂驱动蛋白抑制剂
US7625912B2 (en) Mitotic kinesin inhibitors
JP2005511581A (ja) 有糸分裂キネシン阻害剤
JP2006506401A (ja) 有糸分裂キネシン阻害薬
JP2005515208A (ja) 有糸分裂性キネシン阻害剤
JP2005530806A (ja) 有糸分裂キネシン阻害薬
JP2008535803A (ja) 有糸分裂キネシン阻害剤
JP2007517071A (ja) 有糸分裂キネシン阻害剤
JP2008524329A (ja) 有糸分裂キネシン阻害剤
JP2008530094A (ja) 有糸分裂キネシン阻害剤
CN100403900C (zh) 有丝分裂驱动蛋白抑制剂
JP2008505089A (ja) 有糸分裂キネシン阻害剤
CN1980938B (zh) 有丝分裂驱动蛋白抑制剂
JP2008505094A (ja) 有糸分裂キネシン阻害剤
US20070149553A1 (en) Mitotic kinesin inhibitors
JP2008510012A (ja) 有糸分裂キネシン阻害剤
JP2008533144A (ja) 有糸分裂キネシン阻害剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100531

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100531

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101102

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20110329